|Bid||3.4100 x 800|
|Ask||3.7000 x 1400|
|Day's Range||3.4100 - 3.6100|
|52 Week Range||1.1800 - 5.4900|
|Beta (5Y Monthly)||0.51|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge,.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.